– ‘RLS can fall to a substantial negative impact on quality of life of patients with the chronic inability or staying asleep, which can cause daytime fatigue, – decreased interest in usual activities, ‘said Andrew Witty, President of Pharmaceuticals Europe, ‘The data show that Adartrel effective in improving symptoms of RLS which sleep disorders and improve the quality this this decision is patients and physicians to their. Of a new option, offer to treat this common, debilitating condition ‘.. RLS is a neurological movement disorder characterized by an uncontrollable urge to move the legs and painful or distressing sensations in the limbs. These sensations are sometimes described by patients as creeping, crawling, burning or pulling. The symptoms are getting worse and worse in the evening on the night with rest and improve with movement.
Adartrel Is First Restless legs syndrome treatment, a favorable decision from the European Commission received.
GlaxoSmithKline today announced that the a positive decision on a positive decision on the application for authorization for Adartrel? . To treat moderate to severe idiopathic RLS GSK now expects national marketing authorizations for Adartrel be exhibited in all member states of the European Union in May 2006.And for more than 70 other countries. AACR marshals the whole spectrum out of knowledge from the cancers community toonsUp to accelerate progress into the prevention, diagnosis and treat cancer through high-quality scientific and educational programs. There encourages innovative, deserving research grants. The AACR Annual Meeting pulls more than 17,000 participants the share the latest discoveries and developments in the fields Specific meetings during the whole year present novel data across a plurality of issues of cancer research, treatment and care of patients AACR releases five great peer-reviewed journals Cancer Research, Clinical Cancer Research.